Open AccessColchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk
Author(s) -
Е. С. Енисеева,
AUTHOR_ID,
К. V. Protasov,
AUTHOR_ID
Publication year - 2021
Publication title -
sibirskoe medicinskoe obozrenie
Language(s) - English
Resource type - Journals
eISSN - 2500-0136
pISSN - 1819-9496
DOI - 10.20333/25000136-2021-6-12-21
Subject(s) - medicine , colchicine , acute coronary syndrome , inflammation , residual risk , coronary heart disease , disease , cardiology , intensive care medicine , myocardial infarction
Inflammation plays an important role in atherosclerotic plaque destabilisation and the development of cardiovascular complications. Suppression of its activity in order to reduce residual inflammatory risk in atherosclerotic cardiovascular diseases remains an urgent and unresolved problem to the date. Over the recent years, evidence of the effectiveness of such an approach in secondary prevention of coronary heart disease has been obtained. The purpose of this review was to analyse modern literature on the effect of anti-inflammatory therapy with colchicine on the prognosis of patients with coronary heart disease. The review was carried out using the search for papers published in the PubMed and ClinicalTrials databases within the period from 2007 to 2021. The search was carried out using the keywords «colchicine», «inflammation», «atherosclerosis», «coronary heart disease» and «acute coronary syndrome». The anti-inflammatory and antiatherogenic effects of colchicine are discussed. The paper presents results of studies devoted to the use of colchicine in chronic and acute coronary syndrome, including the key ones LoDoCo2 (2020) and COLCOT (2019) which provided evidence of the effect of the drug on the disease outcome. The issues of safety and prospects of colchicine application in clinical practice for reduction of the residual inflammatory risk in patients with coronary heart disease are addressed.